2009-03-2

Basic information

• Product Name: N-Methyl-5-methoxy-1H-indole-3-ethanamine
• Synonyms: 5-Methoxy-3-[2-(methylamino)ethyl]-1H-indole;N-Methyl-5-methoxy-1H-indole-3-ethanamine;N,O-dimethylserotonin
• CAS NO: 2009-03-2
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 0
• Mol File: 2009-03-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 374.5°C at 760 mmHg
• Flash Point: 180.3°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 8.34E-06mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Sparingly)
• CAS DataBase Reference: N-Methyl-5-methoxy-1H-indole-3-ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methyl-5-methoxy-1H-indole-3-ethanamine(2009-03-2)
• EPA Substance Registry System: N-Methyl-5-methoxy-1H-indole-3-ethanamine(2009-03-2)

Safety Data

• Hazardous Substances Data: 2009-03-2(Hazardous Substances Data)

Usage

Uses

5-Methoxy-N-methyl-1H-Indole-3-ethanamine is a serotonin 5-HT2A receptor agonist.

Definition

ChEBI: A tryptamine derivative hahing a methoxy group at position 5 of the indole portion and a methyl substituent on the side-chain nitrogen.

InChI:InChI=1/C12H16N2O/c1-13-6-5-9-8-14-12-4-3-10(15-2)7-11(9)12/h3-4,7-8,13-14H,5-6H2,1-2H3

Upstream product

• 109396-21-6 N-[2-(5-methoxy-indol-3-yl)-ethyl]-N-methyl-toluene-4-sulfonamide 
• 608-07-1 2-(5-methoxyindol-3-yl)ethylamine 
• 79-22-1 methyl chloroformate 
• 66-83-1 5-methoxytryptamine hydrochloride 
• 104510-12-5 N-(2-(5-methoxy-1H-indol-3-yl)ethyl)formamide 
• 102016-76-2 N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide 
• 68935-49-9 5-methoxy-3-(2-nitroethyl)-1H-indole 
• 1006-94-6 5-methoxylindole 
• 61-54-1 tryptamine 
• 205384-46-9 1-hydroxy-N-methoxycarbonyl-N-methyltryptamine 
• 205384-45-8 2,3-dihydro-N-methoxycarbonyl-N-methyltryptamine 
• 63637-70-7 methyl (2-(1H-indol-3-yl)ethyl)(methyl)carbamate 
• 58635-45-3 methyl 2-(1-H-indol-3-yl)ethylcarbamate 
• 61-49-4 [2-(1H-indol-3-yl)-ethyl]-methylamine 

Downstream Products

• 1516902-87-6 5-(4-bromobenzyloxy)-2-({[2-(5-methoxy-1H-indole-3-yl)ethyl]methylamino}methyl)-chromen-4-one 
• 1516902-73-0 5-(4-bromobenzyloxy)-4-oxo-4H-chromene-2-carboxylic acid [2-(5-methoxy-1H-indol-3-yl)ethyl]methylamide 
• 96096-55-8 5-methoxy-N-methyl-N-isopropyltryptamine 

Relevant articles and documents

Lewis Acid Catalyzed Displacement of Trichloroacetimidates in the Synthesis of Functionalized Pyrroloindolines

The pyrroloindoline core is found in many natural products. These structures often differ at the C3a position, which may be substituted with an oxygen, nitrogen, or sp3- or sp2-hybridized carbon. Utilizing a trichloroacetimidate leaving group, a diversity-oriented approach to these structures has been developed. The trichloroacetimidate intermediate allows for the rapid incorporation of anilines, alcohols, thiols, and carbon nucleophiles. This method was applied in the synthesis of arundinine and a formal synthesis of psychotriasine.

Aromatic heterocyclic derivative and application thereof in medicine

The invention provides aromatic heterocyclic derivatives or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, which are used for treating Alzheimer's disease. The invention also discloses pharmaceutical compositions containing the compounds and a method for treating Alzheimer's disease by using the compounds or the pharmaceutical compositions provided by the invention.

MELATONIN DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL DYSFUNCTIONS

The present invention relates to compounds of the general formula (1): wherein R1, R2, R3, R4 and R5 are H or a moiety of the formula : -(R6)n-R7; with R6 is a is an alkyl chain and R7 is, a moiety selected in the group consisting of -Cn,H2n2,+I, a cycloalkyl moiety, -N(Cn,H2n,+I)(Cn,H2n,+1), -NH-cycloalkyl, -O(Cn,H2n'+I), -0-cycloalkyl, =O, =S, -NO2, -I, -Br, -Cl, -F, -CF3, -OCF3, -COOH, -S03H, -P03H2, -CN, A3 and A4 are, C, N,O or S;m is from 0 to 2; and to their use for the treatment and/or prevention of diseases and conditions mediated by the imbalance of acetylcholine, and for treating and/or preventing glutamate excitotoxicity.